---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-222189"
form_type: "8-K"
ticker: "TECX"
cik: "0001681087"
company_name: "Tectonic Therapeutic, Inc."
filed_at: "2024-09-19T23:59:59+00:00"
generated_at: "2026-05-31T03:38:44.291543+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Tectonic reports positive Phase 1a data for TX45; Phase 2 doses selected, Phase 1b dose escalated

## Summary
- Phase 1a: TX45 well-tolerated, no immunogenicity, robust PK/PD; Phase 2 doses set at 300 mg SC monthly or every other week.
- Phase 1b hemodynamic trial in PH-HFpEF escalated to 3 mg/kg IV; topline results expected Q2 2025.
- Phase 2 APEX trial screening initiated; topline results anticipated in 2026.
- Full Phase 1a results to be presented at AHA Scientific Sessions November 2024.
- Over 600,000 patients estimated with Group 2 PH-HFpEF; no approved treatments currently.

## SEC filing metadata
- accession: 0001193125-24-222189
- form_type: 8-K
- ticker: TECX
- cik: 0001681087
- company_name: Tectonic Therapeutic, Inc.
- filed_at: 2024-09-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1681087/000119312524222189/0001193125-24-222189-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1681087/000119312524222189/d667336d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-222189
- JSON: https://secwatch.observer/filing/0001193125-24-222189.json
- Plain text: https://secwatch.observer/filing/0001193125-24-222189.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.